PAN2: A Potential Drug Target and Biomarker for the Treatment of Neurodegenerative Disorders

Target Name: PAN2

NCBI ID: G9924

PAN2

PAN2: A Potential Drug Target and Biomarker for the Treatment of Neurodegenerative Disorders

Poly(A)-nuclease (PAN) is a enzyme that plays a crucial role in the regulation of DNA stability and is involved in various cellular processes, including DNA replication, transcription, and repair. PAN2, a subunit of the PAN enzyme, is specifically involved in the processing of poly(A) nucleotides (PANs) in the nucleus of eukaryotic cells. PANs are composed of a core domain containing a single alpha-helicase enzyme and a variable region responsible for specificity.

PAN2 has been implicated in various cellular processes, including the regulation of gene expression, DNA replication, and repair, and has been implicated in the development and progression of various neurodegenerative disorders. Moreover, recent studies have suggested that PAN2 may have potential as a drug target or biomarker for the treatment of neurodegenerative disorders.

Potential Drug Targets

PAN2 has been identified as a potential drug target due to its involvement in the regulation of gene expression and cellular processes that are associated with the development and progression of neurodegenerative disorders. Several studies have suggested that inhibition of PAN2 activity may be effective in treating neurodegenerative disorders.

For example, PAN2 has been shown to play a role in the regulation of microRNA (miRNA) levels, which are small non-coding RNAs that play a crucial role in post-transcriptional gene regulation. miRNA levels are regulated by various factors, including PAN2, and have been implicated in the development and progression of various neurodegenerative disorders.

In addition, PAN2 has been shown to play a role in the regulation of DNA replication, which is a critical process in the development and progression of neurodegenerative disorders. In fact, several studies have suggested that PAN2-mediated regulation of DNA replication may contribute to the development of neurodegenerative disorders.

Potential Biomarkers

PAN2 has also been suggested as a potential biomarker for the diagnosis and monitoring of neurodegenerative disorders. The detection and quantification of PAN2 activity in brain tissue or fluids may provide valuable information about the severity and progression of neurodegenerative disorders.

In addition, the regulation of PAN2 activity has been implicated in the development and progression of various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Therefore, measuring PAN2 activity in brain tissue or fluids may provide valuable information about the risk and prognosis of neurodegenerative disorders.

Conclusion

PAN2 is a protein that plays a crucial role in the regulation of DNA stability and has been implicated in various cellular processes that are associated with the development and progression of neurodegenerative disorders. The regulation of gene expression, DNA replication, and repair are critical processes that are involved in the development of neurodegenerative disorders, and PAN2 is involved in each of these processes.

In addition, PAN2 has been identified as a potential drug target and biomarker for the treatment of neurodegenerative disorders. The inhibition of PAN2 activity may be effective in treating neurodegenerative disorders, and the detection and quantification of PAN2 activity in brain tissue or fluids may provide valuable information about the severity and progression of these disorders.

Future studies are needed to further investigate the role of PAN2 in the development and progression of neurodegenerative disorders and to develop effective treatments based on this understanding.

Protein Name: Poly(A) Specific Ribonuclease Subunit PAN2

Functions: Catalytic subunit of the poly(A)-nuclease (PAN) deadenylation complex, one of two cytoplasmic mRNA deadenylases involved in general and miRNA-mediated mRNA turnover. PAN specifically shortens poly(A) tails of RNA and the activity is stimulated by poly(A)-binding protein (PABP). PAN deadenylation is followed by rapid degradation of the shortened mRNA tails by the CCR4-NOT complex. Deadenylated mRNAs are then degraded by two alternative mechanisms, namely exosome-mediated 3'-5' exonucleolytic degradation, or deadenlyation-dependent mRNA decaping and subsequent 5'-3' exonucleolytic degradation by XRN1. Also acts as an important regulator of the HIF1A-mediated hypoxic response. Required for HIF1A mRNA stability independent of poly(A) tail length regulation

The "PAN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PAN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets